Title
Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh

Permalink
https://escholarship.org/uc/item/80z4f316

Journal
International Journal of Clinical and Experimental Medicine, 2(4)

ISSN
1940-5901

Authors
Rohn, Troy T.
Kokoulina, Polina
Eaton, Cody R.
et al.

Publication Date
2009-11-05

License
CC BY 4.0

Peer reviewed
Original Article
Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh

Troy T. Rohn, Polina Kokoulina, Cody R. Eaton, Wayne W. Poon

Abstract: Despite the wealth of evidence supporting the activation of caspases in Alzheimer’s disease (AD), chronic administration of a caspase inhibitor has never been tested in any animal model system. The purpose of the current report was to identify a suitable animal model that displays caspase activation and cleavage of critical proteins associated with AD, and secondly, to undertake a pilot study utilizing the novel caspase inhibitor, quinolyl-valyl-O-methylaspartyl-[2, 6-difluorophenoxy]-methyl ketone (Q-VD-OPh). Analysis of 12 month-old TgCRND8 mice, which represent an early-onset animal model for AD, indicated the activation of caspase-7 as well as the cleavage of tau and the amyloid precursor protein (APP). Having established that TgCRND8 mice represent a suitable model system to target caspases therapeutically, a prophylactic study was initiated utilizing Q-VD-OPh. Three month-old TgCRND8 mice were injected intraperitoneally three times a week for three months with 10 mg/kg Q-VD-OPh and compared to control mice injected with vehicle. Although there was no apparent effect on extracellular Aβ deposition, chronic treatment with Q-VD-OPh did prevent caspase-7 activation and limited the pathological changes associated with tau, including caspase cleavage. These preliminary findings suggest that further studies examining the utility of Q-VD-OPh as a potential therapeutic compound for the treatment of AD are warranted.

Key words: Caspase; TgCRND8 mice, Alzheimer’s disease, Q-VD-OPh, amyloid, tau

Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extensive neuronal loss leading to cognitive impairment and dementia. AD is diagnosed based upon the extent of senile plaques composed of Aβ and NFTs containing abnormally phosphorylated and truncated tau [1]. Currently, there is strong support for the amyloid cascade hypothesis, and many of the current therapeutic strategies now in clinical trials involve some aspect of modifying Aβ production or clearance [2]. Despite these advances, recent clinical trials targeting Aβ have been disappointing [3]. It is important, therefore, to identify new potential drug targets for the treatment of AD.

An overwhelming body of evidence supports a role for the activation of caspases and cleavage of critical cellular proteins in the human AD brain. Evidence demonstrating the activation of various caspases including caspase 3, 6, 8, and 9, to the cleavage of target proteins such as APP, actin, fodrin, tau and GFAP have supported a role for caspases in promoting the pathology underlying AD (for recent reviews see, [4, 5]). More recently, studies conducted with transgenic AD mice have provided further evidence that caspase activation plays a pivotal role in the initiation and progression of the pathology associated with AD [6-8]. These studies support the notion that administration of caspase inhibitors could be an effective strategy in the treatment of AD and the critical next step is to test directly whether inhibitors of caspases prevents pathology following administration in animal models of AD.

In order to test whether pharmacological inhibition of caspases is a valid approach, it is necessary to have an appropriate AD animal model...
Caspase activation in TgCRND8 mice

model that exhibits caspase activation as well as the cleavage of critical target proteins. TgCRND8 mice represent an early-onset AD mouse model that exhibit extensive Aβ deposits and neuritic pathology by as early as 3 months [9, 10], an important consideration with chronic treatment of a compound. The goal of the present report was to determine if caspase activation and cleavage of target proteins occurs in TgCRND8 mice and if so, to examine if treatment with the novel caspase inhibitor, Q-VD-OPh prevents any pathology associated with TgCRND8 mice. The results of this study demonstrated the presence of activated caspase-7 and caspase-cleaved fragments of tau in the TgCRND8 brain, which was prevented following chronic administration of Q-VD-OPh. Although further studies are needed, these findings support the utility of Q-VD-OPh as a potential therapeutic compound for the treatment of AD.

Materials and methods

Tissue acquisition

Mice were anesthetized with pentobarbital, perfused with saline, and the brains rapidly removed. Brains were divided into hemispheres and 1 hemisphere sunk in 4% phosphate-buffered paraformaldehyde, while the other hemisphere was snapped frozen at −50°C in isopentane. Mouse brains were mounted coronally and sectioned serially at 50 µm on a vibratome, and stored for immunohistochemistry.

Immunohistochemistry

Free-floating 50 µm-thick serial sections were used for immunohistochemical and immunofluorescence studies as previously described [11]. Antibody dilutions were the following: mAb MC-1 (1:500), mAb PHF-1 (1:400), anti beta-amyloid mAb 1560 clone 6E10 (1:400, Chemicon), rabbit active caspase-7 (1:100, Oncogene), rabbit active caspase-3 (1:50, BD Pharmingen), rabbit tau caspase-cleavage product (CCP) (1:100, in house antibody), APPccp (1:100, in house antibody) and mAb TauC3 (1:100, Chemicon). For Aβ visualization, antigen retrieval was accomplished by pre-treating tissue sections in 95% formic acid for 5 minutes followed by three washes in Tris buffered saline. Antigen visualization was determined using ABC complex (ABC Elite immunoperoxidase kit, Vector labs), followed by DAB substrate (Vector Labs). For immunofluorescence co-localization studies, antigen visualization was accomplished using an Alexa fluor 488-labeled tyramide (green, Ex/Em = 495/519) or streptavidin Alexa Fluor 555 (red, Ex/Em = 555/565), both from Invitrogen (Carlsbad, CA). For these studies, brain tissue was collected from 12 month-old TgCRND8 mice (n=6) as well as age-matched NonTg control mice (n=6).

Western blot analysis

Sample preparation was according to Oddo et al., [12]. Western blot analysis was performed utilizing the One-Step™ Advanced Western mouse kit according to manufacturer’s instructions (GenScript Corporation, Piscataway, NJ). All samples were analyzed for protein content using the BCA assay (Pierce) to ensure equal protein loading.

Treatment of TgCRND8 mice with Q-VD-OPh

Stock solutions of Q-VD-OPh (SM Biochemicals, Yorba Linda, CA) were prepared in DMSO and diluted in sterile PBS solution prior to injection. A final concentration of 10 mg/kg was chosen based on previous reports indicating neuroprotection at this concentration of Q-VD-OPh [13-15]. Three-month old mice were divided into two groups: control, vehicle (n=3) or treated (n=2). Mice were injected i.p. three times a week with either Q-VD-OPh or vehicle for a total time period of 3 months.

Results

In order to test whether pharmacological inhibition of caspases is a valid approach, it is necessary to have an appropriate AD animal model that exhibits caspase activation as well as the cleavage of critical target proteins. TgCRND8 mice are characterized as a “single” transgenic model containing a double mutant of human APP (KM670/671NL + V717F) under the control of the PrP gene promoter [9]. In addition, TgCRND8 mice represent an early-onset AD mouse model that exhibit extensive Aβ deposits and neuritic pathology by as early as 3 months [9, 10], an important consideration with chronic treatment of a compound. As an initial approach, 12 month-old TgCRND8 mice were examined for the caspase-cleavage of tau using two different site-directed anti-
Caspase activation in TgCRND8 mice

Figure 1. Caspase activation in 12 month-old TgCRND8 mice. A) Representative bright-field micrograph illustrating Aβ deposition in TgCRND8 mice utilizing the 6E10 mAb (1:400). B) Double-label immunofluorescence image with mAb 6E10 to detect extracellular Aβ deposits (red) and a polyclonal TauCCP antibody to detect caspase-cleaved tau (arrows, green). C) Representative image using TauC3 indicated the presence of caspase-cleaved tau within plaque-rich regions. D) Semi-quantitative analysis of the number of extracellular plaques labeled with 6E10 (blue bar), the TauCCP antibody (red bar) and TauC3 (green bar). N = 6 different animals ± S.D. E) Western blot analysis of brain extracts probed with the mAb TauC3 (1:500) indicating the presence of caspase-cleaved tau in all four TgCRND8 mice with weak labeling in only one of four age-matched NonTg control mice. Bottom panel represents loading control blot following stripping and reprobing using a rabbit antibody to beta-actin (1:400). Data are representative of three independent experiments. F) Representative IH staining utilizing an antibody (APPccp) that detects caspase-cleaved APP. Staining with APPccp was localized within plaques of the neocortex. G) Representative IH analysis in TgCRND8 mice depicting staining with an antibody to active caspase-7. Caspase-7 labeling was evident in plaques and within neurons in the vicinity of plaques (G, arrows). H) Double-label immunofluorescence overlap image from a representative TgCRND8 mouse showing colocalization of active caspase-7 (green) together with the apoptotic label, propidium iodide (red). Propidium iodide staining was only evident in neuronal cell bodies that were also labeled with active caspase-7 (arrows, H). All scale bars represent 10 µm except for Panel C, which represents 20 µm.
Caspase activation in TgCRND8 mice

bodies. Figure 1A displays the typical plaque staining observed in 12 month-old TgCRND8 mice following staining with the mAb 6E10, an anti-Aβ antibody. In Figure 1B, double-label immunofluorescence studies were performed to determine whether caspase-cleaved tau co-localized with Aβ in plaque-rich regions. In this case, experiments were undertaken using the monoclonal antibody to Aβ, 6E10 and the rabbit polyclonal antibody, TauCCP [16]. As shown in Figure 1B (arrows), neuronal cell bodies containing caspase-cleaved tau were found within the vicinity of plaques. It is noteworthy that TauCCP-positive neurons displayed cell bodies that were shrunken and condensed in appearance, characteristic features of cells undergoing apoptosis. We confirmed the results with TauCCP using a similar caspase-cleavage antibody to tau (TauC3) developed by Gamblin et al. [17]. Like the TauCCP antibody, TauC3 labeling was found within plaque-rich regions (Figure 1C).

A semi-quantitative analysis indicated that TauC3 and TauC3 labeled less than half the number plaques as were present following staining with mAb 6E10 (Figure 1D). These data indicate that only a subset of plaques actually contain caspase-cleaved tau suggesting that Aβ deposition and caspase activation may not be causally related. Western blot analysis using the TauC3 antibody confirmed the presence of caspase-cleaved tau in 12 month-old TgCRND8 mice (Figure 1E).

Next, we tested whether APP is cleaved by caspases using a site-directed caspase-cleavage product antibody to APP. This antibody, termed APPccp, selectively recognizes the fragment of APP generated by caspase-mediated cleavage of APP following cleavage at position D739 [18]. Evidence for caspase-cleaved APP was evident in TgCRND8 mice, with punctate labeling in plaque regions (Figure 1F). Experiments were also performed to examine the extent of caspase-3 activation in 12 month-old TgCRND8 mice. Surprisingly, we found evidence for caspase-7 activation not caspase-3 within plaque regions of 12 month-old TgCRND8 mice (Figure 1G, arrows). There was no evidence for the activation of caspase-3 using several antibodies to the active domain of the enzyme (data not shown). The identification of caspase-7 as the major executioner caspase activated in TgCRND8 mice is a novel finding and to our knowledge no other human or animal studies have implicated the involvement of this caspase in Alzheimer’s disease. To confirm the presence of active caspase-7 in neurons undergoing apoptosis, double-label immunofluorescence experiments were carried out utilizing propidium iodide, a general marker for apoptotic cells. As shown in Figure 1H, strong co-localization of the two markers within shrunken cell bodies was evident in plaque-rich regions of TgCRND8 indicating a causal relationship between the activation of caspase-7 and the execution of apoptosis.

Based on these preliminary observations, we hypothesize that caspases are activated in TgCRND8 mice and contribute to the processing of APP and tau. Taken together, these data suggest TgCRND8 mice represent a good model to test whether pharmacologic inhibition of caspases is a feasible approach for preventing the pathology associated with these mice.

Because caspase-7 appears to be a critical executioner caspase activated in TgCRND8 mice, we assessed whether Q-VD-OPh is capable of inhibiting this caspase in vitro. We confirmed that Q-VD-OPh is a potent inhibitor of caspase-7 with an IC50 of 48 nM utilizing a cell-free assay consisting of human recombinant caspase-7, Q-VD-OPh, and the substrate AMC-DEVD-pNa (Figure 2A). The calculated IC50 of 48 nM for inhibiting caspase-7 by Q-VD-OPh is well in line with known IC50 values (25-400 nM) for other caspases including caspase -1, 3, 8, 9, 10, and 12 (Product sheet, SM Biochemicals).

Having established that TgCRND8 mice represent a suitable model system to target caspases therapeutically, a small pilot study was initiated utilizing Q-VD-OPh. Three-month old mice were divided into two groups: control, vehicle (n=3) or treated (n=2). Mice were injected i.p. three times a week with either Q-VD-OPh (10 mg/kg) or vehicle for a total time period of 3 months. By the end of three months, 2 mice from the control group survived and 1 mouse from Q-VD-OPh-treated survived. Importantly, we do not believe the death associated with the treatment group was drug-related. There were no signs of toxicity as far as animal behavior, weight loss, motor dysfunction, or tumor formation (physical observations). It should be noted that TgCRND8 mice have a
propensity for seizure-related deaths and since an equal number from the treatment group and vehicle died, we do not believe these deaths to be associated with Q-VD-OPh per se.
Following treatment, mice were sacrificed and brain sections were examined for Aβ utilizing the mAb 6E10 by immunohistochemistry. Results from immunohistochemistry indicated that the number of Aβ plaques appeared equivalent in the Q-VD-OPh-treated mouse as compared to the vehicle controls (Figure 2B-D). In this case, plaques appeared more diffuse and were not core plaques that we observed in 12 month-old animals. Based on these data, it appears that Q-VD-OPh does not prevent Aβ deposition.

Double-labeling immunofluorescence experiments were performed to assess whether Q-VD-OPh prevented caspase-7 activation. In this case, Aβ was visualized using the 6E10 mAb (red, Figure 2E-J) together with a rabbit active caspase-7 antibody (green, Figure 2E-J). While Q-VD-OPh treatment did not prevent Aβ deposition (Figure 2F), it did appear to limit the extent of caspase-7 activation (Figure 2E) as compared to vehicle controls (Figure 2H).

We also examined the extent of caspase-cleaved tau using a specific antibody (TauC3) in TgCRND8 mice following treatment with Q-VD-OPh. Immunohistochemical analysis indicated that despite the apparent lack of effect on Aβ deposition, Q-VD-OPh treatment appeared to attenuate caspase-cleaved tau present within degenerating astrocytes (middle panel, Figure 2L, arrows) and within plaques (Figure 2M). The staining of TauC3 within astrocytes was widespread throughout all brain regions examined and was largely prevented following treatment with Q-VD-OPh. These data suggest that caspase activation and cleavage of tau lie downstream to Aβ production and deposition. Interestingly, we obtained very similar results to TauC3 by utilizing MC-1, an antibody that recognizes an aberrant folded conformational change in tau, which is one of the earliest steps in tau pathology [19, 20]. As depicted in Figure 3A and B, MC-1 immunolabeling was widespread in vehicle-control animals and appeared to be found predominantly within astrocytes (Figure 3A and B). We confirmed the presence of MC-1 immunolabeling within astrocytes following double-label immunofluorescence experiments using MC-1 and an antibody to GFAP (arrow, Figure 3B). In ad-
Caspase activation in TgCRND8 mice

In Figures 2 and 3 suggest that although caspase inhibition has little effect on Aβ deposition, it does prevent pathological changes to tau.

Discussion

Numerous studies have implicated the activation of caspases as well as the cleavage of critical proteins associated with the pathology in AD [5]. Caspases are indispensable for the execution of apoptosis, being responsible for the phenotypic characteristics of apoptosis following the cleavage of critical cellular proteins [21]. In AD, however, the aberrant activation of caspases may not only contribute to the neurodegeneration associated with this disease, but may also promote the underlying pathology including the facilitation of NFT formation. Thus, caspase activation and cleavage of tau may be a proximal event in NFT formation [16, 17]. Based upon the available data, caspases represent potential therapeutic targets for the treatment of AD [4]. Precedent for caspase inhibition in other neurodegenerative disorders has been demonstrated. For example, in a study by Li et al., the authors used the pan-caspase inhibitor N-benzyloxy carbonyl-Val-Ala-Asp fluoromethyl-ketone (Z-VAD-fmk) to treat transgenic mice expressing mutant human SOD1, a model of amyotrophic lateral sclerosis (ALS) [22]. In this case, administration of Z-VAD-fmk delayed disease onset and mortality in ALS mice [22]. Caspase inhibition also delayed disease progression and death in a mouse model of Huntington’s disease [23], and increased the survival of dopaminergic neurons in a rat model of Parkinson’s disease [24]. An important caveat to these studies is that they all involved acute treatment with Z-VAD (<14 days) and therefore, whether such a strategy would be effective in a chronic disease such as AD is unknown.

The goal of the present study was to examine the feasibility of chronically treating TgCRND8 mice with a novel caspase inhibitor, Q-VD-OPh. Q-VD-OPh has been shown to be a potent and selective caspase inhibitor [25, 26]. Improvements over Z-VAD-fmk include potency, stability, and cell permeability [25]. In addition, Q-VD-OPh has demonstrated efficacy in affording CNS neuroprotection in animal models of Parkinson’s, Huntington’s disease and stroke [14, 27]. Moreover, this compound is not toxic to cells even at extremely high concentrations and is systemically active [26]. Therefore, Q-VD-OPh would seem to be an ideal candidate to test whether pharmacological inhibition of caspases in vivo can prevent the pathology associated with AD.

In order to test whether pharmacological inhibition of caspases is a valid approach, it is necessary to have an appropriate AD animal model that exhibits caspase activation as well as the cleavage of critical target proteins. Experiments in 12 month-old TgCRND8 mice confirmed that caspase activation and cleavage of target proteins occurs in this animal model of AD. In this regard, evidence for the activation of caspase-7 and cleavage of tau as well as APP was demonstrated to occur particularly in plaque-rich regions. Following validation that TgCRND8 mice represent a suitable model system to target caspases therapeutically, a small pilot study was initiated employing Q-VD-OPh. In this case, a prophylactic approach was taken by treating young TgCRND8 mice beginning at 3 months of age. Treatment with Q-VD-OPh consisted of 3 injections per week systemically for three months. Importantly, no visible adverse effects were noted following treatment with Q-VD-OPh, in particular tumor formation. Pathological examination of brain regions revealed that chronic treatment with Q-VD-OPh did not prevent Aβ deposition, but prevented caspase activation. These results are in line with previous studies in post-mortem human AD and animal model studies indicating that caspase activation most likely lies downstream of Aβ formation [5]. In addition, Q-VD-OPh limited pathological changes to tau including cleavage and early conformational changes. The data concerning TauC3 and MC-1 were intriguing: staining in vehicle controls indicated labeling predominantly within reactive astrocytes and not within neuronal populations. In support of these findings is a recent study by Reyes et al., who demonstrated robust tau nitration within reactive astrocytes of the AD brain [28]. Moreover, these authors showed that a subset of nitrated-
positive astrocytes also labeled with the antibody Alz-50, a very similar antibody to MC-1 that recognizes a conformation-dependent tau epitope [28]. This suggests that in AD, the same factors that may influence tau alterations in neurons may also affect tau expressed in glial cells. The potential consequence of astrocytes containing alterations of tau in young TgCRND8 mice is unknown and will require further investigation.

In summary, there are numerous neurodegenerative disorders in which caspases specifically and apoptosis in general are known to play a role including AD. However, despite the wealth of evidence supporting the activation of this family of proteases in these disorders, chronic administration of a caspase inhibitor has never been tested in any animal or model system. We now show that TgCRND8 mice appear to be an excellent animal model to examine the role of caspases, displaying caspase activation and cleavage of target proteins including tau. Further, the results of the small pilot study with the novel caspase inhibitor, Q-VD-OPh, represent the first time whereby chronic administration of a caspase inhibitor was undertaken. While Q-VD-OPh did not prevent Aβ deposition, it did limit the extent of caspase activation and pathological changes to tau in plaque regions and within reactive astrocytes. Although additional studies are warranted with Q-VD-OPh using a larger data set and also examining whether chronic treatment improves memory deficits in TgCRND8 mice, results from this pilot study support the feasibility of caspases as drug targets for the treatment of AD.

Acknowledgments

Funded by NIH/NCRR grant #P20RR016454 and a grant from the American Health Assistance Foundation (AHAF) to T.T.R. This work was also supported by a gracious donation from the KO AD Foundation (Boise, ID) to T.T.R. The authors also acknowledge Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY) for providing both the MC-1 and PHF-1 antibodies used in this study.

Address correspondence to: Troy T. Rohn, PhD, Department of Biology, Science/Nursing Building, Room 228, Boise State University, Boise, Idaho, 83725, Tel: 208-426-2396, Fax: 208-426-4267, Email: trohn@boisestate.edu

References


Caspase activation in TgCRND8 mice


307
Caspase activation in TgCRND8 mice


